智通财经APP讯，康希诺(688185.SH)披露2025年第三季度报告，公司前三季度实现营收6.93亿元，同比 增长22.13%;归母净利润1444万元，同比扭亏为盈;扣非净利润亏损8286万元;基本每股收益0.06元。 ...

公告显示，公司前三季度营业收入692,568,069.77元，同比增加22.13%，归属上市公司股东的净利润 14,440,145.56元。 炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 10月27日消息，康希诺发布三季度报告。 公告显示，十大流通股东中，HKSCCNOMINEESLIMITED、CHAMPDENLLC、香港中央结算有限公 司为新进流通股东。 责任编辑：小浪快报 ...

智通财经记者 | 李科文 智通财经编辑 | 谢欣 10月23日晚间，百克生物发布公告称，因工作调整，孙晚丰申请辞去公司第六届董事会职工代表董事及副总经理职务。 辞任后，其将继续担任公司董事长助理。 受经济下行、新生儿数量下降、疫苗接种意愿降低、市场竞争加剧等因素影响，国内疫苗行业开始集体承压。这种压力 在2025年集中显现。 针对公司高管变动对后续战略是否有影响，百克生物于10月24日向智通财经表示，明年的工作战略尚在确定过程中，暂 不作出评价。 与此同时，市场亦有消息称，康泰生物副总裁于冰亦调任董事长助理。对此，10月24日，智通财经致电康泰生物董秘 办。接线工作人员称，于冰目前没有岗位变动，仍为公司副总裁。如有变动将依规披露，其他人事安排暂不清楚。 自2024年年末起，国内疫苗行业具有销售背景的高管更替频繁。 孙晚丰最初供职于康华生物（维权），在生物疫苗营销领域拥有丰富经验。2024年11月，康华生物公告称，公司副总裁 孙晚丰因个人原因辞职。一个月后，他加入百克生物，出任总经理助理。2025年2月，孙晚丰进一步升任为百克生物董 事、副总经理。 智通财经观察发现，A股10家疫苗上市公司中，仅有5家在2025 ...

（原标题：HPV疫苗纳入免疫规划，重塑百亿市场与公共健康格局） 21世纪经济报道记者季媛媛 中国HPV疫苗免费接种政策在经历了从地方试点到省级推广后，如今已经进入到了国家免疫规划。 9月11日，国新办举行"高质量完成'十四五'规划"系列主题新闻发布会，介绍"十四五"时期卫生健康工作 发展成就。据介绍，今年国家将推出面向适龄女生的HPV疫苗接种服务，并且将HPV疫苗纳入国家免疫 规划，保护女性的健康。 这场始于地方试点的健康行动终于升级为国家战略，标志着中国宫颈癌防控进入新阶段。 HPV（人乳头瘤病毒）感染可引发多种疾病，高危型HPV与宫颈癌、外阴癌、阴道癌、肛门癌、口咽癌 等多种恶性肿瘤的发生密切相关，低危型HPV则是引发尖锐湿疣的主要原因。部分男性亦存在HPV感染 及相关疾病风险。接种HPV疫苗是当前公认安全、有效的一级预防手段，可显著降低HPV感染及其相关 疾病的发病率。 为了提高HPV疫苗接种率，全国多地陆续启动了适龄人群HPV疫苗接种惠民活动，以进口九价HPV疫苗 为例，可以减免最后一剂次接种费用。眼下， 我国HPV疫苗接种以二价、四价、九价为主，在推进 HPV进免规的过程中，是否会优先考虑覆盖特定价 ...

申联生物于2019年10月28日在上海证券交易所科创板上市，发行数量5,000万股，发行价格8.80元/股， 保荐机构（主承销商）为国信证券股份有限公司，保荐代表人为吴风来、王攀。 上市首日，申联生物盘中最高价报36.88元，为该股上市以来最高价。 中国经济网北京9月11日讯 申联生物(688098.SH)近日发布2025年半年度报告。报告期内，该公司实现营 业收入1.22亿元，同比下降3.68%；实现归属于上市公司股东的净利润-1286.97万元，上年同期 为-3450.80万元；实现归属于上市公司股东的扣除非经常性损益的净利润-1679.62万元，上年同期 为-3544.40万元；经营活动产生的现金流量净额为-3938.91万元，上年同期为-80.56万元。 2024年，申联生物实现营业收入30,341.47万元，同比增长0.64%；实现归属于上市公司股东的净利 润-4,474.01万元，上年同期为3,151.87万元；实现归属于上市公司股东的扣除非经常性损益的净利 润-4,837.65万元，上年同期为2,506.98万元；经营活动产生的现金流量净额为8,936.20万元，上年同期为 352.55万元。 ...

Group 1 - Beijing will launch free HPV vaccination for first-year female students starting in September to enhance health protection for young women [1] - The HPV vaccine is currently the most economical and effective method for preventing cervical cancer, with high protective efficacy against pre-cancerous lesions and cancers caused by HPV types 16 and 18 [1] - Eligible first-year female students, aged 9 and above, can receive the domestically procured bivalent HPV vaccine for free, following a two-dose immunization schedule [1] Group 2 - District CDCs will coordinate with local education departments to designate vaccination clinics for each school, with vaccinations primarily conducted at the school’s designated clinic [2] - Parents or guardians must accompany students to the vaccination site, and a 30-minute observation period is required post-vaccination [2] - Students wishing to self-pay for the quadrivalent or nonavalent HPV vaccines can make appointments through various platforms, provided they meet the vaccination criteria [2]

Group 1: Financial Performance - The company's operating revenue for the first half of 2025 was ¥59,961,774.27, representing a year-on-year increase of 68.77% [3] - The net profit attributable to shareholders decreased by 17.71% to ¥20,797,156.80 [3] - The net profit after deducting non-recurring gains and losses was -¥12,784,853.85, showing a year-on-year increase of 40.04% [3] - As of the end of the reporting period, total assets amounted to ¥6,912,395,737.39, with net assets attributable to shareholders at ¥5,918,534,037.40 [3] Group 2: Dividend Policy - The 2024 dividend plan is to distribute ¥2 per 10 shares, with a total cash dividend of ¥8 per 10 shares for 2025 [4] - The average annual net profit attributable to shareholders over the past three years was ¥5.284 billion, with cumulative cash dividends of ¥706.4 million, resulting in a payout ratio of 133.69% [4] - The company aims to enhance the stability and predictability of cash dividends while increasing the average payout ratio [4] Group 3: Vaccine Industry Insights - The global human vaccine market grew from $27.7 billion in 2017 to $46 billion in 2021, with a compound annual growth rate (CAGR) of 13.5%, projected to reach $83.1 billion by 2025 and exceed $131 billion by 2030 [4] - In China, the overall vaccination rate for influenza vaccines is approximately 3%, significantly lower than the rates in developed countries [5] - The CDC reported that the vaccination rates for the 2023-2024 flu season in the U.S. were 55.4% for ages 6 months to 17 years, 44.9% for adults, and 69.7% for seniors aged 65 and above [5] Group 4: Market Strategy and Future Growth - The company has established a sales network covering over 2,500 disease control centers across more than 30 provinces, achieving over 70% coverage [5] - To improve accessibility and market competitiveness, the company adjusted the price of its quadrivalent influenza vaccine starting June 5, 2024 [6] - Future growth points include the development of rabies and tetanus vaccines, with the company also advancing clinical trials for new products like mRNA vaccines [6]

Core Viewpoint - The company, Ai Mei Vaccine, is poised for significant growth with the upcoming commercialization of key vaccine products and a reduction in R&D expenses, leading to a strong financial outlook for 2025 and beyond [1][2] Group 1: Financial Performance - Ai Mei Vaccine reported stable revenue for the first half of 2025, supported by the impending launch of four major vaccine products [1] - The company is expected to achieve profitability by 2026, with sales projected to grow at a compound annual growth rate (CAGR) of 45% from 2025 to 2027 [2] Group 2: Product Development - Four major vaccine products are nearing commercialization: - The registration application for the updated rabies vaccine has been accepted - The 13-valent pneumonia conjugate vaccine has applied for registration and completed on-site verification - The 23-valent pneumonia polysaccharide vaccine has completed Phase III clinical serum testing and is entering the statistical unblinding phase - The updated high-efficiency diploid rabies vaccine is in Phase III clinical trials, with a registration application expected in 2026 [1] - The company has 20 vaccine products in development across 12 disease areas, with 23 clinical approvals and 24 ongoing clinical trials, including 7 innovative Class 1 vaccines [1] Group 3: Market Expansion - Ai Mei Vaccine has successfully entered the African market with its quadrivalent meningococcal polysaccharide vaccine and is registering in Central Asia - The rabies vaccine has made its debut in the Central American market - The hepatitis B vaccine is actively undergoing registration processes in Southeast Asia, while the hepatitis A vaccine is progressing in South Asia [1]

Group 1 - The stock price of CanSino (688185.SH) closed at 80.87 yuan, reflecting a decline of 4.66% [1] - CanSino was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on August 13, 2020, with an issuance of 24.8 million shares at a price of 209.71 yuan per share [1] - The company raised a total of 5.201 billion yuan, with a net amount of 4.979 billion yuan after deducting issuance costs, which was 3.979 billion yuan more than the original plan [1] Group 2 - The funds raised were intended for several projects, including the construction of the second phase of the production base, vaccine development, cold chain logistics system, and working capital [1] - The issuance costs for CanSino amounted to 221 million yuan, with underwriting fees accounting for 205 million yuan [2] - CITIC Securities, as the lead underwriter, received an allocation of 496,000 shares, representing 2.00% of the total shares issued, with an investment amount of 104 million yuan [2]

Group 1 - The core viewpoint of the news is that Beijing Kexing Holdings' subsidiary has developed an adsorbed tetanus vaccine, which has received approval from the National Medical Products Administration, providing more options for tetanus prevention [1] - The Kexing adsorbed tetanus vaccine utilizes nanometer-level adjuvant technology and purification process innovations, achieving breakthroughs in immunogenicity and safety, thus offering a superior solution for tetanus prevention [1] - The vaccine features an adjuvant with a particle size of only 300 nanometers, significantly enhancing the adsorption efficiency of the antigen and improving the stability of the formulation compared to traditional adjuvants [1] Group 2 - The phase III clinical study of the Kexing adsorbed tetanus vaccine shows that the geometric mean concentration (GMC) of antibodies is higher than that of the control vaccine, indicating good safety [1] - Tetanus remains a serious public health issue in countries and regions with inadequate immunization programs, with an estimated annual incidence of approximately 1 million cases and a death toll of 300,000 to 500,000 [1] - The vaccine is intended for post-exposure prevention of tetanus in cases of injury and for pre-exposure prevention in high-risk populations [1] Group 3 - Kexing Group is actively expanding its presence in the injury field, with the adsorbed tetanus vaccine being a key product in the company's "injury combination product" strategy [2] - In addition to the vaccine, the company is advancing clinical research on the anti-tetanus toxin monoclonal antibody SNA02-48 injection [2] - The company has also invested in Xingmeng Biotech, which developed the innovative drug Kexib, approved for passive immunotherapy for adult rabies virus exposure in 2024 [2]